Fairvalue-Calculator Fairvalue-Calculator
EN DE

KMPHARMACEUTICAL Co (225430) Fair Value & Analysis

Financial Services · KR · Market cap 11.6B KRW

Price1,749 KRW
Fair Value231.27 KRW
Upside-86.8%
Quality95/100
Evidence: Low Range 184.65 KRW – 279.82 KRW

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

KMPHARMACEUTICAL Co (225430) currently trades at 1,749 KRW, while our model-based Fair Value estimate is 231.27 KRW — implying the stock looks roughly 86.8% overvalued today. We read business quality at 95/100 (high quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

KMPHARMACEUTICAL Co.,Ltd. engages in the manufacture, wholesale, and retail of oral care, beauty care, and other daily necessities in South Korea and internationally. The company offers toothpastes, toothbrushes, cosmetics, masks, hand cream, toothbrush and toothpaste, kids toothbrush, and baby finger toothbrush sets. It also provides children's safety gargles, baby and light wipes, wet wipes, and steam eye masks; shampoos, body washes, sun creams, moisture creams, wrinkle functional cosmetics, and hair dyes; and dehumidifiers and hand sanitizers. The company was founded in 2001 and is headquartered in Pyeongtaek-si, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is KMPHARMACEUTICAL Co (225430) undervalued?
As of Jun 26, 2026, our model estimates a fair value of 231.27 KRW versus a price of 1,749 KRW — about −87% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 225430?
Our 21-model fair value for KMPHARMACEUTICAL Co is 231.27 KRW (as of Jun 26, 2026), built from audited fundamentals. The current price is 1,749 KRW.
What is the quality score of 225430?
KMPHARMACEUTICAL Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.